Postbiotic Supplements Market Size, Share, Growth and Forecast, 2025-2035

Postbiotic Supplements market size was valued at USD 198.6 million in 2025 and is projected to reach USD 574.1 million by 2035.

By Form (Capsules and Tablets, Powder and Granules, Soft-gel and Chews); By Application (Immune Support, Gut and Digestive Health, Metabolic and Weight Management, Skin, Mood and Others); By Distribution Channel (Drug Stores and Pharmacies, Online Retail, Health and Beauty Stores, Supermarkets and Hypermarkets); By Region (Asia Pacific, North America, Europe, Latin America, Middle East & Africa)

SKU: CR7733Report Pages: 250Category: Food & BeverageReport Format: PDF, ExcelLast Updated: Nov 19Author: Priyanka MorReviewed by: Deepti AgrawalPreferred on

Market Report Metrics

Revenue, 2025 -
USD 198.6 million
Forecast Year -
2035
CAGR (2025–2035)
11.20%
Report Coverage
Global

Heat-killed strains move from Japan into global brands

The global postbiotic supplements market was valued at USD 198.6 million in 2025 and is projected to increase from USD 220.8 million in 2026 to USD 574.1 million by 2035, registering a CAGR of 11.20% during 2026–2035. Demand comes from adults who want immune and digestive support in a tablet, capsule or chew that needs no refrigeration, and from brands that can add inactivated bacteria to formats where live strains would die. Asia Pacific held the largest regional share, 48.0% in 2025, and is also the fastest-growing region at 11.6% a year, because Japanese makers have sold heat-killed lactic acid bacteria tablets for years. North America follows with 28.0%, built on yeast fermentates and pasteurized strains sold under dietary supplement rules. The main commercial change is that probiotic strain owners now launch inactivated versions of their own strains, while the main restraint is that the European Union still accepts no gut or immune claim for these ingredients.

Which products count as a postbiotic supplement?

The market counts finished dietary supplements in which the active ingredient is a preparation of inanimate microorganisms or their components, such as heat-killed lactic acid bacteria, pasteurized Akkermansia, yeast fermentates and butyrate blends, valued at the price the brand owner receives. Brands buy the ingredient from strain owners on supply contracts, then sell capsules, tablets, powders and chews through drugstores, online stores and practitioners.

Postbiotic drinks, yogurts, fortified foods, cosmetics, pet products and feed additives are excluded, although several strain owners sell the same ingredient into those uses. Combination products that pair live probiotics with a postbiotic are counted when the postbiotic is named on the label as an active ingredient.

Postbiotic Supplements Market Size, Share, Growth and Forecast, 2025-2035
Report Attribute Details
Details
Historical Period
2018–2025
Base Year
2025
Forecast Period
2025–2035
Postbiotic Supplements Size 2025
USD 198.6 million
Postbiotic Supplements CAGR
11.20%
Postbiotic Supplements Size 2035
USD 574.1 million

Postbiotic Supplements Market Insights

  • The market is projected to rise from USD 198.6 million in 2025 to USD 574.1 million by 2035 at 11.20% a year, with chewable formats and weight management claims adding the most new value.
  • Asia Pacific held 48.0% of 2025 value and grows fastest at 11.6% a year, as Japanese heat-killed lactic acid bacteria brands expand abroad.
  • Immune Support led applications with 41.0% of 2025 value, because the largest postbiotic brands were built on immune clinical trials.
  • Kirin's iMUSE supplement sales rose about 30% in 2025 and overseas LC-Plasma ingredient shipments about 50%, according to the company.
  • Probi launched Rham271h, its first postbiotic, at Vitafoods Europe in May 2026, joining Kerry and dsm-firmenich in selling inactivated strains.

Immune tablets lead while chews and weight claims grow

Why do capsules and tablets hold most postbiotic value?

Based on form, the market is categorized into capsules and tablets, powder and granules, and soft-gel and chews. Capsules and Tablets led with 54.0% of 2025 value because the main clinical doses fit one small unit, such as the 500-milligram EpiCor capsule and Kirin iMUSE tablets sold in 30-day packs. Soft-gel and Chews grow fastest at 12.6% a year, as inactivated strains survive heat and moisture, and Concordix said in September 2026 that it would show chewable postbiotic concepts using Kerry and dsm-firmenich strains at SupplySide Global. Brands moving into chews gain shelf space in children and beauty ranges, while powder sticks stay strongest in Japan.

Why does immune support lead postbiotic applications?

Based on application, the market is categorized into immune support, gut and digestive health, metabolic and weight management, and skin, mood and others. Immune Support led with 41.0% of 2025 value because the two largest postbiotic brands, Kirin LC-Plasma and Cargill EpiCor, were built on immune trials, and Cargill lists seven human immune studies for EpiCor. Metabolic and Weight Management grows fastest at 13.1% a year, as a 2026 Nature Medicine trial in 90 adults found that those taking pasteurized Akkermansia regained 1.2 kilograms over a 24-week maintenance phase, against 3.2 kilograms on placebo. Brands with human metabolic data can charge the highest daily prices.

How do buyers reach postbiotic products across channels?

Based on distribution channel, the market is categorized into drug stores and pharmacies, online retail, health and beauty stores, and supermarkets and hypermarkets. Drug Stores and Pharmacies led with 35.0% of 2025 value because Japanese chains carry the largest brands, and Tsuruha lists three 30-day packs of Kirin iMUSE immune care tablets at JPY 7,798. Online Retail grows fastest at 12.6% a year, as Kirin and Blackmores launched an LC-Plasma powder on Blackmores Taiwan e-commerce in March 2025 and U.S. Akkermansia capsules sell mainly through online and practitioner stores. Online sellers gain repeat subscriptions, while supermarkets carry few postbiotic lines.

Segment GroupLeading Sub-segmentShare, 2025Fastest-growing Sub-segmentCAGR, 2026–2035
By FormCapsules and Tablets54.0%Soft-gel and Chews12.6%
By ApplicationImmune Support41.0%Metabolic and Weight Management13.1%
By Distribution ChannelDrug Stores and Pharmacies35.0%Online Retail12.6%

Akkermansia costs over four times a yeast fermentate daily

Brands price postbiotic products per daily serving, and the spread follows the clinical evidence and the cost of growing the strain. A yeast fermentate such as EpiCor works out to about USD 0.45 a day at list price, while pasteurized Akkermansia, an anaerobic organism that is hard to grow at scale, costs about USD 2.05 a day. Japanese heat-killed lactic acid bacteria tablets sit between them at about JPY 87 a day. Price moves with fermentation yields, licensing fees paid to strain owners and the strength of approved claims, so brands with exclusive human data keep the widest margins, while blends that add a small postbiotic dose compete on price.

Offer or segmentTypical price or feeBasis
Pasteurized Akkermansia capsules, 30 x 150 mgUSD 61.43 per bottleVitacost list price, November 2026
EpiCor yeast fermentate capsules, 60 x 500 mgUSD 27.19 per bottleSwanson list price, November 2026
Kirin iMUSE immune care tablets, three 30-day packsJPY 7,798 per setTsuruha online list price, November 2026
Prebiotic, probiotic and butyrate postbiotic capsules, 60 countUSD 44.95 per bottleMaryRuth's list price, November 2026

Request a Free Sample

Fill in your details and we'll send you a free sample report.

  • Sample data tables & charts
  • Research methodology

Stability, Japanese immune brands and new trials lift use

Shelf stability lets brands use formats closed to live strains

Inactivated bacteria do not need to stay alive in the bottle, so brands can put them into tablets, gummies and drinks that would kill most live probiotics. The International Scientific Association for Probiotics and Prebiotics, writing in Nature Reviews Gastroenterology & Hepatology, defined a postbiotic in May 2021 as a preparation of inanimate microorganisms and their components that confers a health benefit on the host. Cargill states a three-year shelf life for EpiCor postbiotic and cites more than 15 published studies behind it. Morinaga Milk said in September 2025 that its heat-killed MCC1848 strain is already used in more than 100 Japanese products, including candies and vinegar drinks, which widens demand beyond capsules. Contract makers lacking cold storage gain most, because they can run postbiotic lines on standard tablet and gummy equipment.

Japanese immune brands are scaling heat-killed bacteria

Japanese companies built the largest consumer base for postbiotic products by selling heat-killed lactic acid bacteria as everyday immune care, and that base is now growing abroad. Kirin reported that sales of its iMUSE supplement series rose about 30% in 2025 and FANCL Meneki Support about 20%, while its LC-Plasma strain is now sold by 12 partner companies in 24 functional food products. Kirin and Blackmores also developed an LC-Plasma powder together, showing that the strain now travels beyond Japanese brands. Brand owners in Asia that license proven Japanese strains gain a faster route to market than those funding new trials.

Heat map of postbiotic ingredient selection criteria by brand type across human trials, shelf stability, low price and regulatory file
Figure 1: Relative importance of postbiotic ingredient selection criteria by brand type, 2025. Source: Credence Research assessment

Download Free Sample

Metabolic trials give postbiotics a new claim base

Weight and glucose support is becoming the second claim base for postbiotic products, because inactivated strains now carry regulatory approvals and controlled trial data in this area. Commission Implementing Regulation (EU) 2022/168 authorized pasteurised Akkermansia muciniphila as a novel food in February 2022, for food supplements used by adults at up to 34 billion cells a day. ADM says its heat-treated HT-BPL1 strain showed results similar to the live BPL1 strain, which reduced waist circumference in 2 clinical studies, and in August 2021 it launched HT-BPL1 in Nourished 3D-printed gummies in the U.K. The 2026 Nature Medicine result noted in the segment section adds human weight maintenance data and supports adoption. Strain owners holding metabolic data gain pricing power over immune-only rivals.

Older adults form the largest buying group

Supplement use rises sharply with age, and postbiotic suppliers are aiming at older buyers with muscle, immune and mobility claims. The CDC reported in May 2026 that 75.9% of U.S. adults aged 60 and over used a dietary supplement in 2021–2023, against 46.3% of adults aged 20 to 39. Women used supplements more than men, at 66.1% against 53.9%. dsm-firmenich said in February 2026 that two human trials of its Humiome Post LB strain in adults aged 55 and over were under way. Brands selling to older adults gain a large, repeat-buying group, provided they can cite human data for the claim.

Strain owners launch inactivated twins of probiotics

Probiotic strain owners are launching inactivated twins

Probiotic suppliers are shifting toward inactivated versions of their own clinically studied strains to address brand demand for heat-stable formats, creating openings for postbiotic lines across tablets, gummies and drinks. Probi announced on May 5, 2026, that it had launched Rham271h, its first postbiotic, at Vitafoods Europe, based on its Lacticaseibacillus rhamnosus 271 strain. Kerry launched Plenibiotic, its first postbiotic ingredient, made from Lactobacillus casei 327, in February 2024 for gut and skin health in humans and pets. dsm-firmenich sells Humiome Post LB, a heat-treated blend of L. delbrueckii and L. fermentum. Strain owners reuse existing safety and strain data, which cuts development time, while newcomers without a strain library find it harder to compete.

Mood and cognition claims are emerging beside immune care

Ingredient suppliers are shifting postbiotic positioning toward mood and cognition to address buyers who already take immune products, creating openings in stress and sleep ranges. Morinaga Milk launched LAC-Living+, a heat-killed Lactobacillus helveticus MCC1848 ingredient, for international markets in September 2025, starting in Asia Pacific. Two 4-week placebo-controlled trials at 5 billion heat-killed cells a day, one in Brain Sciences with 46 nursing students and one in Beneficial Microbes with 58 participants, reported better positive emotion scores, although negative emotion scores did not change. The dsm-firmenich trials in older adults also assess cognition, with results expected in the second half of 2026. Evidence remains small and short, so brands that make mood claims carry more regulatory risk than immune brands do.

Timeline of postbiotic launches and rule changes from Kerry Plenibiotic in February 2024 to the end of EU Akkermansia data protection in March 2027
Figure 2: Postbiotic launches and rule changes, 2024–2027. Source: company releases, MFDS, Japan CAA and EU Regulation 2022/168

Download Free Sample

A second pasteurized Akkermansia supply is an opening

Brands that want pasteurized Akkermansia but cannot license the first supplier are an underserved customer group, and a second source is now forming. HealthBiome says it holds FDA new dietary ingredient acknowledgments for its HB05P pasteurized Akkermansia, the first received in December 2024. Korea's Ministry of Food and Drug Safety approved HB05P as a functional ingredient, No. 2025-71, on Dec. 24, 2025, with a claim that it may help maintain muscle strength affected by aging. HealthBiome plans capsule launches in Korea and the U.S. in 2026 and B2B supply deals. In the EU, Regulation 2022/168 keeps data protection for the first authorized supplier until March 1, 2027, which opens that market to other applicants.

Children's gummies are an opening for immune postbiotics

Parents buying immune products for school-age children are an underserved group, because postbiotic chews avoid live cultures and fit gummy formats. A Cargill-funded trial in Pediatric Research gave 256 Canadian children aged 4 to 12 a daily 500-milligram EpiCor gummy through the 2022–2023 cold season, and children on placebo were 1.7 times more likely to use medication. The CDC found that 41.9% of U.S. children aged 2 to 11 used a supplement in 2021–2023. MaryRuth's already sells an organic kids multivitamin gummy with two postbiotic strains. Brands with pediatric data can enter functional jellies and gummies ranges, although child claims face tighter review.

Claim rules, GMP costs and thin evidence slow growth

European claim rules block gut and immune wording

The EU treats the word probiotic as a health claim, and FoodNavigator reported in January 2025 that EFSA has substantiated no specific probiotic health claim. Postbiotic brands therefore cannot state gut or immune benefits on EU labels unless an authorized vitamin or mineral claim sits on the product. About 10 member states have national guidance allowing the term, which splits the market by country. European brands and importers are most exposed, because they must market through science content rather than labels.

Japanese GMP rules raise costs for small brands

Japan made Good Manufacturing Practice mandatory for tablet, capsule and powder products sold under Foods with Function Claims, with enforcement from Sept. 1, 2026. The rule followed the Kobayashi red yeast rice case, which had reached 1,614 medical cases and five deaths by May 2024. The rule adds plant audits and adverse event reporting, which raise fixed costs for every supplement line. Small Japanese brands without certified plants are most exposed, while contract manufacturing firms gain orders.

Thin human evidence weakens newer ingredients

Many postbiotic ingredients reach shelves with safety files but little human efficacy data, which limits what brands can claim and buyers can trust. Superbrewed Food launched Thryvia, a heat-killed Clostridium tyrobutyricum ingredient, in August 2026, backed by an FDA GRAS letter of February 2024 that covers use as a protein source. Its human study measured perceived digestive comfort over four weeks, without a disclosed sample size. Brands using such ingredients are exposed if regulators or retailers ask for clinical support.

No common dose unit makes products hard to compare

Postbiotic labels state doses in different units, so buyers cannot compare products, and this slows retailer listing. Probi sets a minimum effective dose of 10 billion TFU for Rham271h, The Akkermansia Company labels 30 billion TFU per capsule, and Morinaga uses 5 billion heat-killed cells a day. No regulator has adopted a standard count for inactivated cells, and Credence Research found no official testing method for them. Smaller brands buying unbranded material are most exposed to quality disputes.

Asia Pacific leads on Japanese heat-killed bacteria

RegionValue, 2025 (USD million)Share, 2025CAGR, 2026–2035
Asia Pacific95.348.0%11.6%
North America55.628.0%11.0%
Europe31.816.0%10.1%
Latin America8.94.5%11.4%
Middle East & Africa7.03.5%11.5%

Asia Pacific leads on Japanese heat-killed bacteria

Asia Pacific held 48.0% of 2025 postbiotic supplements value and grows fastest at 11.6% a year. This lead exists because Japan has the longest history of heat-killed lactic acid bacteria tablets and Kirin and Morinaga now export their strains. Japanese drugstores carry immune tablets beside vitamins, and Korea opened a functional ingredient route with the HB05P approval. Credence Research puts Japan at about 75% of regional value. The September 2026 GMP rule will remove some small Japanese brands, which favors large brand owners.

North America grows on yeast fermentates and Akkermansia

North America held 28.0% of 2025 postbiotic supplements value and grows at 11.0% a year. The U.S. leads the region, because dietary supplement rules let brands launch new postbiotics after a GRAS letter or a new dietary ingredient notification. Cargill makes EpiCor in the U.S., and The Akkermansia Company sells pasteurized Akkermansia capsules through online and practitioner channels. High supplement use among adults over 60 supports immune and muscle claims. Credence Research puts the U.S. at about 88% of regional value.

Lollipop chart of U.S. dietary supplement use in 2021–2023, adults 60 and over 75.9%, adults 40 to 59 60.3%, adults 20 to 39 46.3%, children 2 to 11 41.9%
Figure 3: U.S. dietary supplement use by age, 2021–2023. Source: CDC, NCHS Data Brief No. 561

Download Free Sample

Europe is held back by claim rules

Europe held 16.0% of 2025 postbiotic supplements value and grows at 10.1% a year, the slowest regional rate. Growth lags because brands cannot print gut or immune claims for these ingredients. The region still hosts major strain owners, including Kerry in Ireland, Probi in Sweden and dsm-firmenich, which sell postbiotic ingredients worldwide. Pasteurized Akkermansia is the only postbiotic with an EU novel food authorization for supplements, and wider supply after March 2027 is the main upside for European brands.

Latin America buys imported brands

Latin America held 4.5% of 2025 postbiotic supplements value and grows at 11.4% a year. Demand is concentrated in Brazil and Mexico through imported U.S. and Japanese brands and local brands buying ingredients from global suppliers. Credence Research found no regional postbiotic strain producer and no public sales data, so this estimate rests on import prices and the regional share of supplement sales. That remains an evidence gap for any buyer sizing the region. Online marketplaces are the main route for new brands entering Brazil and Mexico.

Middle East and Africa remains a small import market

Middle East & Africa held 3.5% of 2025 postbiotic supplements value and grows at 11.5% a year. Demand comes from imported immune and gut products sold in Gulf pharmacies and South African health stores. Credence Research found no local postbiotic production and no public sales data, so the estimate rests on imports of finished goods. Brands with halal certificates, such as EpiCor, which Cargill lists as Certified Halal, are better placed to win Gulf pharmacy listings.

Donut chart of 2025 postbiotic supplements market shares, Asia Pacific 48.0%, North America 28.0%, Europe 16.0%, Latin America 4.5%, Middle East and Africa 3.5%
Figure 4: Postbiotic supplements market share by region, 2025. Source: Credence Research estimates

Download Free Sample

Launches and approvals marked 2024 to 2026

DevelopmentStatus and market relevance
In February 2024, Kerry launched Plenibiotic, its first postbiotic ingredient, made from Lactobacillus casei 327 for gut and skin health.Commercial launch; the ingredient is offered to supplement, food and pet brands.
In September 2025, Morinaga Milk launched LAC-Living+, a heat-killed Lactobacillus helveticus MCC1848 ingredient, for international markets.Commercial launch with an initial Asia Pacific focus; the strain is already sold in Japan.
In December 2025, Korea's Ministry of Food and Drug Safety approved HealthBiome's HB05P pasteurized Akkermansia as a functional ingredient.Regulatory approval; capsule launches in Korea and the U.S. are planned for 2026.
In May 2026, Probi launched Rham271h, the postbiotic version of its Rham271 strain, at Vitafoods Europe.Commercial launch for supplement, food and beverage brands.
In August 2026, Superbrewed Food launched Thryvia, a heat-killed Clostridium tyrobutyricum ingredient, for digestive and immune products.Commercial launch; further human studies are described as ongoing.

Inactivation method and dose units decide quality

  • Heat inactivation kills lactic acid bacteria while keeping cell wall parts that immune cells recognize, and it suits tablet and gummy lines.
  • Pasteurization of anaerobic strains is used for Akkermansia, which is hard to keep alive outside the gut, and it gives a stable powder for capsules.
  • Yeast fermentation produces whole fermentates such as EpiCor, which contain metabolites, cell wall fragments and proteins in one dried ingredient.
  • Cell counting by TFU replaces colony counts for dead cells, but methods differ between suppliers, which complicates label comparison.

Need a Custom Version of This Report?

Tailor the scope, geography, or segments to your exact requirements.

  • Custom geography or segment scope
  • Direct access to our analyst team

Ingredient owners compete on clinical files and claims

Competition splits between strain owners that sell branded ingredients and brands that build products around them. Kirin and Morinaga lead in Japan with heat-killed lactic acid bacteria, and Kirin also sells finished iMUSE products. Cargill supplies EpiCor to many U.S. brands, while ADM, Kerry, dsm-firmenich and Probi license inactivated strains from their probiotic libraries. The Akkermansia Company and HealthBiome compete in pasteurized Akkermansia, the highest-priced niche. Superbrewed Food is a new entrant with a heat-killed anaerobic strain. Finished brands such as MaryRuth's and Dr. Emil Nutrition combine postbiotics with prebiotics and probiotics in multi-ingredient formulas. Suppliers win through human trial data, regulatory files and stability, because brands need claims they can defend. Buyers should weigh exclusivity and claim support as heavily as ingredient price.

Strain owners with human trials hold the margin

Supply sits with a small group of strain owners, including Kirin, Cargill, ADM, Kerry, dsm-firmenich, Morinaga and Probi, which hold the clinical files and patents, and many brand owners that buy their ingredients. Entry barriers are high for strain owners because human trials and regulatory files take years, but low for brands that license a branded ingredient. Margins sit mostly with brands that hold exclusive human data and with strain owners that charge licensing fees, while unbranded blends compete on price.

Companies profiled and their roles in this market

CompanyTypeRole in the market
Kirin Holdings Company, LimitedStrain owner and brandLC-Plasma heat-killed Lactococcus lactis in iMUSE tablets and partner products
Cargill, IncorporatedIngredient supplierEpiCor yeast fermentate postbiotic sold to supplement brands
ADMIngredient supplierHT-BPL1 heat-treated Bifidobacterium lactis for metabolic health products
Kerry Group plcIngredient supplierPlenibiotic Lactobacillus casei 327 postbiotic for gut and skin health
dsm-firmenichIngredient supplierHumiome Post LB heat-treated lactobacilli blend for digestive and healthy aging uses
Morinaga Milk Industry Co., Ltd.Strain ownerLAC-Living+ heat-killed Lactobacillus helveticus MCC1848 for mood support
The Akkermansia CompanySpecialistPasteurized Akkermansia muciniphila MucT capsules for weight and glucose support
Probi AB (Symrise)Ingredient supplierRham271h inactivated Lacticaseibacillus rhamnosus 271 launched in 2026
HealthBiomeSpecialistHB05P pasteurized Akkermansia with Korean muscle claim and U.S. NDI files
Superbrewed Food, Inc.SpecialistThryvia heat-killed Clostridium tyrobutyricum for digestive and immune products
MaryRuth's OrganicsBrand ownerKids multivitamin gummies with postbiotic strains and butyrate gut capsules
Dr. Emil NutritionBrand ownerTotal Gut Complex capsules combining prebiotic, probiotic and postbiotic ingredients

Clinical files matter more than live counts

Credence Research's view is that the postbiotic supplements market will be decided by clinical files rather than by cell counts, because inactivated strains cannot rely on the live-culture message that sold probiotics. Immune Support keeps 41.0% of 2025 value on Japanese and U.S. immune trials, but weight and muscle claims will add the most new value if human data hold. Strain owners with exclusive data and regulatory files will keep the best margins. Brands selling small postbiotic doses inside blends face price pressure and should expect closer questions from retailers.

Estimates rest on company disclosures and prices

The report uses 2025 as the base year and forecasts to 2035. The earlier Credence Research estimate was rebuilt from a bottom-up check of company sales disclosures, retail prices and supplement use statistics, which gave a much larger 2025 value, while the earlier growth rate was kept. Regional shares, segment splits and the Japanese supplement share are Credence Research estimates. Sources include regulator documents, company releases, health statistics and peer-reviewed trial reports; no interviews or surveys are claimed.

Metabolic and chewable formats carry growth to 2035

Metabolic and Weight Management should grow at 13.1% a year to 2035, the fastest application rate in postbiotic supplements. The market should reach USD 574.1 million by 2035, with immune products still the largest application and Asia Pacific the largest region. Growth through 2027 depends on human trial results for weight and muscle claims, the end of EU data protection for pasteurized Akkermansia and the effect of Japanese GMP rules. These projections are modeled estimates and would shift with regulatory decisions and trial outcomes.

Metabolic trial data and claim rules set the upside

The range depends mainly on how fast metabolic claims gain human evidence and on whether regulators in Europe and Japan ease or tighten claim and manufacturing rules. Strong weight maintenance data and new Akkermansia suppliers would lift prices and volumes, while a safety scare or weak trial results would push brands back toward cheaper live probiotics.

ScenarioCAGR, 2026–2035Value, 2035What has to hold
Downside9.2%USD 487.6 millionWeak metabolic trial results and tighter claim rules push brands back to live probiotics
Base11.20%USD 574.1 millionSteady immune demand, gradual metabolic adoption and more strain owners entering
Upside12.9%USD 658.1 millionPositive weight maintenance trials and new Akkermansia suppliers widen adoption in the U.S. and Asia

Frequently Asked Questions

How big is the postbiotic supplements market?
The market was valued at USD 198.6 million in 2025 and is projected to reach USD 574.1 million by 2035, growing at 11.20% a year during 2026–2035, according to Credence Research estimates built from company disclosures and retail prices.
What is the size of the postbiotic food supplements market?
Postbiotic food supplements, the capsules, tablets, powders and chews counted here, were worth USD 198.6 million in 2025 by Credence Research estimates, while postbiotic drinks and yogurts sold in Japan add further value outside this scope.
Who are the leading postbiotic suppliers and manufacturers?
Buyers most often shortlist Kirin, Cargill, ADM, Kerry, dsm-firmenich, Morinaga Milk, The Akkermansia Company, Probi, HealthBiome and Superbrewed Food, depending on the health claim, the strain and the regulatory file each brand needs for its market.
Which postbiotic manufacturing companies launched new ingredients recently?
Kerry launched Plenibiotic in February 2024, Morinaga Milk launched LAC-Living+ abroad in September 2025, Probi launched Rham271h in May 2026 and Superbrewed Food launched its heat-killed Thryvia ingredient in August 2026.
Why are postbiotic ingredients used in functional foods and chews?
Inactivated strains survive heat, moisture and long storage, so brands can add them to tablets, gummies and drinks, and Cargill states a three-year shelf life for its EpiCor yeast fermentate ingredient.
Are shelf-stable postbiotic products more expensive than probiotics?
Prices vary widely, from about USD 0.45 a day for EpiCor capsules to about USD 2.05 a day for pasteurized Akkermansia capsules, depending on the strain, the cost of growing it and the strength of its human evidence.
How large is the postbiotic market in Germany, France and Italy?
Europe held 16.0% of 2025 value by Credence Research estimates, and growth in Germany, France and Italy is limited because EU rules accept no gut or immune claim for these ingredients.
Which region leads the postbiotic supplements market?
Asia Pacific leads with 48.0% of 2025 value and grows fastest at 11.6% a year, supported by long-established Japanese heat-killed lactic acid bacteria brands from Kirin and Morinaga Milk.

Table of Content

Chapter 1 Market Segmentation

  • 1.1 Segmentation Framework
    • 1.1.1 Product and Service Classification
    • 1.1.2 Application and End-Use Classification
    • 1.1.3 Technology and Solution Classification
    • 1.1.4 Customer and Distribution Channel Classification
    • 1.1.5 Geographic Segmentation
    • 1.1.6 Market Segment Definitions and Boundaries
  • 1.2 By Form
    • 1.2.1 Capsules and Tablets
    • 1.2.2 Powder and Granules
    • 1.2.3 Soft-gel and Chews
  • 1.3 By Application
    • 1.3.1 Immune Support
    • 1.3.2 Gut and Digestive Health
    • 1.3.3 Metabolic and Weight Management
    • 1.3.4 Skin, Mood and Others

Chapter 2 Introduction

  • 2.1 Report Objectives and Scope
  • 2.2 Product Definition and Industry Terminology
  • 2.3 Market Inclusions and Exclusions
  • 2.4 Research Process
    • 2.4.1 Primary Research and Expert Interviews
    • 2.4.2 Secondary Research and Source Review
    • 2.4.3 Top-Down and Bottom-Up Estimation
    • 2.4.4 Data Triangulation and Verification
  • 2.5 Market Size Measurement Basis
    • 2.5.1 2025: USD 198.6 million → 2035: USD 574.1 million
  • 2.6 Historical and Forecast Reference Periods
    • 2.6.1 Historical Period: 2018-2025
    • 2.6.2 Base Year: 2025
    • 2.6.3 Forecast Period: 2025-2035
  • 2.7 Research Assumptions and Limitations

Chapter 3 Executive Summary

  • 3.1 Market Snapshot and Key Findings
  • 3.2 Base-Year Market Size, 2025
  • 3.3 Forecast Market Size, 2035
  • 3.4 Revenue and Volume Growth Outlook
  • 3.5 Key Demand and Supply Indicators
  • 3.6 Leading Market Segments
  • 3.7 Fastest-Growing Market Opportunities
  • 3.8 Regional Performance Highlights
  • 3.9 Technology and Industry Transformation
  • 3.10 Competitive Landscape Summary
  • 3.11 Analyst View and Strategic Implications

Chapter 4 Global Postbiotic Supplements Market Trends and Developments

  • 4.1 Historical Industry Development, 2018-2025
  • 4.2 Recent Market Trends and Developments
  • 4.3 Demand and Customer Behavior Trends
  • 4.4 Technology and Product Innovation
  • 4.5 Artificial Intelligence, Automation and Digitalization
  • 4.6 Local Manufacturing and Supply Chain Realignment
  • 4.7 Industry Partnerships, Mergers and Acquisitions
  • 4.8 Sustainability and Circular Economy Developments
  • 4.9 Government and Private Sector Investment Trends
  • 4.10 Emerging Business Models and Commercialization
  • 4.11 Industry Developments and Announcements

Chapter 5 Global Postbiotic Supplements Market Production, Supply and Demand Analysis

  • 5.1 Demand Trend and Consumption Analysis, 2018-2025
  • 5.2 Demand Forecast, 2025-2035
  • 5.3 Production and Output Trend, 2018-2025
  • 5.4 Production and Output Forecast, 2025-2035
  • 5.5 Installed Capacity and Capacity Utilization
  • 5.6 Company-Wise Production Plants and Statistics
    • 5.6.1 Installed Production Capacity
    • 5.6.2 Actual Production
    • 5.6.3 Planned Capacity and Expansion Targets
  • 5.7 Supply Chain Structure and Procurement Trends
  • 5.8 Supply-Demand Gap and Bottlenecks
  • 5.9 Import Dependence and Sourcing Structure
  • 5.10 Contract Manufacturing and Outsourcing
  • 5.11 Regional Supply and Demand Concentration

Chapter 6 Global Postbiotic Supplements Market Pricing Analysis

  • 6.1 Pricing Structure and Measurement
  • 6.2 Historical Pricing Trends, 2018-2025
  • 6.3 Pricing Outlook, 2025-2035
  • 6.4 Average Selling Price and Unit Economics
  • 6.5 Pricing by Product and Market Segment
  • 6.6 Geographic Pricing Differences
  • 6.7 Key Input, Energy, Labor and Logistics Costs
  • 6.8 Contract Pricing and Purchasing Models
  • 6.9 Pricing Sensitivity and Competitive Positioning
  • 6.10 Price, Margin and Profitability Implications

Chapter 7 Global Postbiotic Supplements Market Dynamics

  • 7.1 Market Growth Drivers
    • 7.1.1 Demand-Side Drivers
    • 7.1.2 Technology and Innovation Drivers
    • 7.1.3 Infrastructure and Investment Drivers
    • 7.1.4 Regulatory and Policy Drivers
  • 7.2 Market Restraints
    • 7.2.1 Cost and Affordability Constraints
    • 7.2.2 Technology and Adoption Barriers
    • 7.2.3 Supply Chain and Operational Constraints
  • 7.3 Market Challenges
    • 7.3.1 Competitive Pressure and Margin Erosion
    • 7.3.2 Skills, Infrastructure and Implementation Gaps
  • 7.4 Emerging Market Opportunities
  • 7.5 Market Dynamics Impact and Time-Horizon Assessment

Chapter 8 Global Postbiotic Supplements Value Chain Analysis

  • 8.1 Industry Value Chain Overview
  • 8.2 Upstream Suppliers and Critical Inputs
  • 8.3 Technology and Component Providers
  • 8.4 Manufacturing or Service Delivery
  • 8.5 Distribution, Channel Partners and Integrators
  • 8.6 Downstream Applications and End Users
  • 8.7 Value Addition and Profit Pools
  • 8.8 Vertical Integration and Outsourcing
  • 8.9 Supplier Concentration and Risk
  • 8.10 Supply Chain Localization and Resilience

Chapter 9 Global Postbiotic Supplements Market Regulations and Policies

  • 9.1 Relevant Laws, Standards and Compliance Frameworks
  • 9.2 Product, Service, Safety and Quality Requirements
  • 9.3 Government Policies, Incentives and Subsidies
  • 9.4 Imports, Exports and Trade Barriers
  • 9.5 Public Procurement and Local Content Requirements
  • 9.6 Environmental and Sustainability Compliance
  • 9.7 Upcoming Policy Changes and Market Implications

Chapter 10 Global Postbiotic Supplements Market Hotspots and Opportunities

  • 10.1 Market Opportunity Mapping and Growth Hotspots
  • 10.2 High-Growth Applications and Customer Groups
  • 10.3 Underserved Markets and White-Space Opportunities
  • 10.4 Emerging Technology and Product Opportunities
  • 10.5 New Capacity and Investment Hotspots
  • 10.6 Market Entry and Expansion Opportunities
  • 10.7 Distribution and Partnership Opportunities
  • 10.8 Near-Term and Long-Term Commercial Potential
  • 10.9 Opportunity Attractiveness and Execution Risks

Chapter 11 Global Postbiotic Supplements Market Outlook, 2025-2035

  • 11.1 Market Size and Analysis
    • 11.1.1 Revenue (Market Measurement: 2025: USD 198.6 million → 2035: USD 574.1 million)
    • 11.1.2 Market Volume and Quantity Sold
    • 11.1.3 Historical Market Size, 2018-2025
    • 11.1.4 Base-Year Market Size, 2025
  • 11.2 Market Forecast, 2025-2035
    • 11.2.1 Revenue Forecast to 2035
    • 11.2.2 Volume Forecast to 2035
    • 11.2.3 CAGR and Year-on-Year Growth
    • 11.2.4 Incremental Revenue Opportunity
  • 11.3 Forecast Assumptions and Scenario Analysis
    • 11.3.1 Base-Case Forecast
    • 11.3.2 Optimistic and Conservative Scenarios
    • 11.3.3 Technology, Pricing and Policy Sensitivities
  • 11.4 Market Attractiveness and Growth Outlook

Chapter 12 Global Postbiotic Supplements Market Segmentation and Outlook

  • 12.1 Segmentation Summary and Market Shares, 2025
  • 12.2 Largest and Fastest-Growing Segments
  • 12.3 By Form - Market Size and Forecast, 2025-2035
    • 12.3.1 Segment Definition and Scope
    • 12.3.2 Historical Market Size, 2018-2025
    • 12.3.3 Revenue Forecast, 2025-2035
    • 12.3.4 Volume Forecast, 2025-2035
    • 12.3.5 Base-Year Market Share, 2025
    • 12.3.6 Segment CAGR and Growth Drivers
    • 12.3.7 Subsegment Market Size and Forecast
      • 12.3.7.1 Capsules and Tablets
      • 12.3.7.2 Powder and Granules
      • 12.3.7.3 Soft-gel and Chews
    • 12.3.8 Subsegment Pricing and Adoption Trends
    • 12.3.9 Leading Suppliers and Competition
    • 12.3.10 Regional Demand and Opportunities
  • 12.4 By Application - Market Size and Forecast, 2025-2035
    • 12.4.1 Segment Definition and Scope
    • 12.4.2 Historical Market Size, 2018-2025
    • 12.4.3 Revenue Forecast, 2025-2035
    • 12.4.4 Volume Forecast, 2025-2035
    • 12.4.5 Base-Year Market Share, 2025
    • 12.4.6 Segment CAGR and Growth Drivers
    • 12.4.7 Subsegment Market Size and Forecast
      • 12.4.7.1 Immune Support
      • 12.4.7.2 Gut and Digestive Health
      • 12.4.7.3 Metabolic and Weight Management
      • 12.4.7.4 Skin, Mood and Others
    • 12.4.8 Subsegment Pricing and Adoption Trends
    • 12.4.9 Leading Suppliers and Competition
    • 12.4.10 Regional Demand and Opportunities
  • 12.5 Segment Growth Comparison
  • 12.6 Segment Attractiveness and Priority Matrix

Chapter 13 Global Postbiotic Supplements End-Use and Application Market Outlook

  • 13.1 End-Use Industry and Customer Demand Structure
  • 13.2 Leading Applications and Customer Groups
  • 13.3 End-Use Market Size, Share and Forecast
  • 13.4 Major End-Use Industry Deep Dives
    • 13.4.1 Customer Requirements and Use Cases
    • 13.4.2 Demand and Replacement Cycles
    • 13.4.3 Technical and Regulatory Considerations
    • 13.4.4 Purchasing and Procurement Models
    • 13.4.5 Leading Vendors and Distribution Channels
    • 13.4.6 Forecast and Commercial Opportunities
  • 13.5 Emerging Applications and Cross-Segment Demand
  • 13.6 End-Use Industry Investment Priorities

Chapter 14 Global Postbiotic Supplements Geographic Market Outlook, 2025-2035

  • 14.1 Regional Market Size and Share, 2025
  • 14.2 Regional Market Forecast, 2025-2035
  • 14.3 Regional Pricing, Production and Demand Differences
  • 14.4 North America
    • 14.4.1 United States
    • 14.4.2 Canada
    • 14.4.3 Mexico
  • 14.5 Europe
    • 14.5.1 Germany
    • 14.5.2 France
    • 14.5.3 Italy
    • 14.5.4 United Kingdom
    • 14.5.5 Spain
    • 14.5.6 Poland
    • 14.5.7 Russia
    • 14.5.8 Netherlands
    • 14.5.9 Belgium
    • 14.5.10 Sweden
    • 14.5.11 Denmark
    • 14.5.12 Norway
    • 14.5.13 Rest of Europe
  • 14.6 Asia Pacific
    • 14.6.1 China
    • 14.6.2 India
    • 14.6.3 Japan
    • 14.6.4 South Korea
    • 14.6.5 Thailand
    • 14.6.6 Indonesia
    • 14.6.7 Vietnam
    • 14.6.8 Malaysia
    • 14.6.9 Australia
    • 14.6.10 Rest of Asia Pacific
  • 14.7 Latin America
    • 14.7.1 Brazil
    • 14.7.2 Argentina
    • 14.7.3 Colombia
    • 14.7.4 Chile
    • 14.7.5 Rest of Latin America
  • 14.8 Middle East
    • 14.8.1 Saudi Arabia
    • 14.8.2 United Arab Emirates
    • 14.8.3 Turkey
    • 14.8.4 Israel
    • 14.8.5 Iran
    • 14.8.6 Rest of the Middle East
  • 14.9 Africa
    • 14.9.1 South Africa
    • 14.9.2 Egypt
    • 14.9.3 Nigeria
    • 14.9.4 Morocco
    • 14.9.5 Rest of Africa
  • 14.10 Regional Investment, Policy and Supply Chain Differences
  • 14.11 Regional Competitive Landscape
  • 14.12 Geographic Growth Hotspots

Chapter 15 Global Postbiotic Supplements Technology, Innovation and Sustainability Outlook

  • 15.1 Technology Landscape and Maturity
  • 15.2 Product, Process and Service Innovation
  • 15.3 AI, Automation and Digital Tools in the Industry
  • 15.4 Technology Adoption and Performance Benchmarking
  • 15.5 Innovation Pipeline and R&D Investment
  • 15.6 Patent and Intellectual Property Trends
  • 15.7 Energy Efficiency and Resource Management
  • 15.8 Sustainability, Recycling and Circularity
  • 15.9 Technology Roadmap, 2025-2035
  • 15.10 Risks of Obsolescence and Technology Substitution

Chapter 16 Global Postbiotic Supplements Market Key Strategic Imperatives

  • 16.1 Growth and Market Entry Priorities
  • 16.2 High-Return Products and Segments
  • 16.3 Pricing, Profitability and Cost Optimization
  • 16.4 Technology Investment and Product Differentiation
  • 16.5 Supply Chain Localization and Resilience
  • 16.6 Distribution and Customer Acquisition
  • 16.7 Partnership, Acquisition and Capacity Strategy
  • 16.8 Regional Expansion Priorities
  • 16.9 Short-, Medium- and Long-Term Actions

Chapter 17 Competition Outlook

  • 17.1 Industry Competition Characteristics
  • 17.2 Market Structure and Concentration
  • 17.3 Market Share and Competitive Positioning, 2025
  • 17.4 Company-Wise Revenue and Product Benchmarking
  • 17.5 Production and Service Capacity Benchmarking
  • 17.6 Technology, Pricing and Differentiation
  • 17.7 Regional Footprint and Distribution Strength
  • 17.8 Mergers, Acquisitions and Strategic Alliances
  • 17.9 New Entrants and Competitive Threats
  • 17.10 Porter's Five Forces and Industry Attractiveness
  • 17.11 Competitive Outlook, 2025-2035

Chapter 18 Company Profiles

  • 18.1 Company Coverage and Selection Criteria
  • 18.2 Kirin Holdings Company, Limited
    • 18.2.1 Business Description
    • 18.2.2 Company Ownership and Geographic Presence
    • 18.2.3 Product and Service Portfolio
    • 18.2.4 Manufacturing and Operating Footprint
    • 18.2.5 Production Capacity and Expansion Plans
    • 18.2.6 Financial Performance and Investment
    • 18.2.7 Market Share and Competitive Position
    • 18.2.8 Technology and Innovation Capabilities
    • 18.2.9 Strategic Alliances or Partnerships
    • 18.2.10 Recent Developments
    • 18.2.11 Growth Strategy and Outlook
  • 18.3 Cargill, Incorporated
  • 18.4 ADM
  • 18.5 Kerry Group plc
  • 18.6 dsm-firmenich
  • 18.7 Morinaga Milk Industry Co., Ltd.
  • 18.8 The Akkermansia Company
  • 18.9 Probi AB (Symrise)
  • 18.10 HealthBiome
  • 18.11 Superbrewed Food, Inc.
  • 18.12 MaryRuth's Organics
  • 18.13 Dr. Emil Nutrition
  • 18.14 Other Relevant Market Participants

Note: Every listed company is profiled on the structure shown under the first company. The company list is preliminary and may change based on research findings, market developments, data availability and client requirements.

Chapter 19 Disclaimer

  • 19.1 Research and Forecast Disclaimer
  • 19.2 Data Source and Estimation Limitations

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.

Methodology

Meet the Team

Priyanka Mor
Priyanka Mor

Senior Consultant

Senior Consultant at Credence Research Inc directing strategic market advisory, cross-border commercial due diligence and enterprise intelligence frameworks for global B2B clients. Combines quantitative modeling with executive advisory, translating macroeconomic variables and supply chain data into go-to-market blueprints, M&A screenings and competitive war-gaming strategies.

Deepti Agrawal

Reviewed by

Deepti Agrawal

Head of Editorial Operations

Related Topics

Tiger Nut Market Size, Share, Growth and Forecast, 2025-2035

Tiger nut market worth USD 212.9 million in 2025 is set to reach USD 398.2 million by 2035 at a 6.46% CAGR as flour, oil and sugar-free horchata widen use.

Yeast Extract Market Size, Share, Growth and Forecast, 2025-2035

Yeast extract market worth USD 2.34 billion in 2025 will reach USD 4.60 billion by 2035, at a 7.00% CAGR as sodium cuts and feed demand lift use.

Asian Sauces, Dressings, and Condiments Market Size, Share, Growth and Forecast, 2025-2035

Asian sauces, dressings and condiments market worth USD 52.00 billion in 2025 will reach USD 85.51 billion by 2035, at a 5.10% CAGR as chili sauces gain.

Australia Caffeinated Beverage Market Size, Share, Growth and Forecast, 2025-2035

Australia caffeinated beverage market worth USD 2.22 billion in 2025 reaches USD 3.87 billion by 2035 at a 5.72% CAGR as energy drinks and zero-sugar colas gain

U.S. Butchery And Meat Processing Market Size, Share, Growth and Forecast, 2025-2035

U.S. butchery and meat processing market worth USD 118.12 billion in 2025 reaches USD 176.53 billion by 2035 at a 4.10% CAGR as tight cattle supply lifts value

US Bakery Items Market Size, Share, Growth and Forecast, 2025-2035

U.S. bakery items market worth USD 48.39 billion in 2025 reaches USD 65.67 billion by 2035 at a 3.10% CAGR as fresh and frozen lines offset flat bread